Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer
about
A Brief Review of Computer-Assisted Approaches to Rational Design of Peptide VaccinesEngineering opportunities in cancer immunotherapyCancer anti-angiogenesis vaccines: Is the tumor vasculature antigenically unique?Identification of hub genes of pneumocyte senescence induced by thoracic irradiation using weighted gene co‑expression network analysisMagnetic Enrichment of Dendritic Cell Vaccine in Lymph Node with Fluorescent-Magnetic Nanoparticles Enhanced Cancer ImmunotherapyAntiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancerAdvances in the study of HLA-restricted epitope vaccines.Recent advances in immunotherapy for non-small-cell lung cancer.Identification of immunogenic LY6K long peptide encompassing both CD4(+) and CD8(+) T-cell epitopes and eliciting CD4(+) T-cell immunity in patients with malignant diseaseTrial Watch: Peptide-based anticancer vaccines.The present status and future prospects of peptide-based cancer vaccines.Induction of tumor inhibitory anti-angiogenic response through immunization with interferon Gamma primed placental endothelial cells: ValloVax™.Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses.Clinical significance of expanded Foxp3⁺ Helios⁻ regulatory T cells in patients with non-small cell lung cancer.Utility of the dual-specificity protein kinase TTK as a therapeutic target for intrahepatic spread of liver cancerImmunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patientsRecent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer.Could mycobacterial Hsp70-containing fusion protein lead the way to an affordable therapeutic cancer vaccine?The critical role of peptide chemistry in the life sciences.Development of Peptide Vaccines in Dengue.Threonine and tyrosine kinase may serve as a prognostic biomarker for gallbladder cancer.Revisiting of cancer vaccine?-Specific immunotherapy comes to field with the biomarker.Trial Watch: Peptide vaccines in cancer therapy.Functional analysis of the DEPDC1 oncoantigen in malignant glioma and brain tumor initiating cells.Immunotherapeutic Targeting of Tumor-Associated Blood Vessels.Identification of an HLA-A2-restricted CD147 epitope that can induce specific CTL cytotoxicity against drug resistant MCF-7/Adr cells.Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.Cell division cycle-associated protein 1 as a new melanoma-associated antigen
P2860
Q24261117-58F1F1C8-0D5E-42AF-9D11-093615A02AFAQ26776373-13A561B2-2D72-42C8-9069-1B5DA07DD29DQ26778150-0DD27ADB-9131-46B4-985F-4B6210BD8E7FQ28396973-8359A384-EDDD-4F1D-B003-780E787EE418Q28598312-031F384B-46C8-4623-81DC-EBB9D05BD5D6Q30399006-279644E2-81B8-412D-AAA8-F6FBA815D762Q33587863-59ACDA9D-8652-4361-8484-4D89075CC693Q34170130-DB144CF1-4841-4400-8E86-530A3225046BQ34290801-27036A62-894F-46A6-B9DE-4500B0186990Q34372937-9C9D1D3F-BCA2-4865-926B-41674C90854EQ34483345-71854924-42DC-4E84-87EA-E0C4549B9966Q34528638-F7C209E4-F480-4AF3-8934-0DEE95ADB52FQ35187503-173FD80F-DF25-48B7-9F47-AEB24E95B8C2Q35569528-3FF9DB7E-919A-400E-B1ED-82C1DD6D46C1Q36336136-5A92FBCC-BB53-4720-B051-619450F5960AQ37251564-E5460503-9EAF-41BE-ADFD-083C6ADDED6EQ37530591-FBB3A029-1BE8-43A7-9606-BBDB093E9849Q38168904-4C58349F-198B-441B-8549-002762B1E5C9Q38286381-62F84B47-B2F5-43EB-AE54-B135CBD99A78Q39044227-321393EF-1BEA-497F-88B8-10547831BD76Q40038715-DDC8E999-95E9-461C-9909-68CA64526172Q41505635-345BFB07-8ADE-48DE-AC7A-AA6F23DA0F91Q42106939-B579D5BD-80AB-4A2B-BA34-18E5860F39A0Q42734544-C5677CA4-28D9-41EA-A10E-D867B53526B1Q48363759-57B0CAF5-F130-4F5B-806A-8A12C7AD2307Q49592831-DFE8A591-63CB-4DC4-B95C-F6B2F064366FQ52349546-831E8756-8A5F-4602-8189-B705F8F432B3Q55190117-BF8FB3BF-38F3-4BC3-A029-BA030098F841Q57719088-DB040A4A-C1D4-43E6-AB2E-5D6BE0ED9836
P2860
Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Multiple therapeutic peptide v ...... ith non-small cell lung cancer
@ast
Multiple therapeutic peptide v ...... ith non-small cell lung cancer
@en
type
label
Multiple therapeutic peptide v ...... ith non-small cell lung cancer
@ast
Multiple therapeutic peptide v ...... ith non-small cell lung cancer
@en
prefLabel
Multiple therapeutic peptide v ...... ith non-small cell lung cancer
@ast
Multiple therapeutic peptide v ...... ith non-small cell lung cancer
@en
P2093
P2860
P356
P1476
Multiple therapeutic peptide v ...... ith non-small cell lung cancer
@en
P2093
Atsushi Yonechi
Hiroshi Yaginuma
Hiroyuki Suzuki
Kazuya Ise
Kazuyoshi Takeda
Mika Hoshino
Mitsukazu Gotoh
Mitsunori Higuchi
Mitsuro Fukuhara
P2860
P2888
P356
10.1186/1479-5876-11-97
P577
2013-04-11T00:00:00Z
P5875
P6179
1043300795